Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 725-730

  Fontana, Elisa ^a,f   Pucci, Francesca ^a   Camisa, Roberta ^a   Bui, Simona ^a   Galdy, Salvatore ^b   Leonardi, Francesco ^a   Negri, Francesca Virginia ^a   Anselmi, Elisa ^c   Losardo, Pier Luigi ^d   Roncoroni, Luigi ^e   Dell'Abate, Paolo ^f   Crafa, Pellegrino ^g   Cascinu, Stefano ^h   Ardizzoni, Andrea ^a  

^a Medical Oncology Unit   (Italy)

^b University Hospital Bolognini Seriate   (Italy)

^c Hospital of Piacenza   (Italy)

^d Radiotherapy Unit   (Italy)

^e General Surgical Clinics and Surgical Therapy   (Italy)

^f UNIVERSITY HOSPITAL OF PARMA   (Italy)

^g UNIVERSITY OF PARMA   (Italy)

^h OSPEDALI RIUNITI   (Italy)

Author keywords

Chemoradiation; Colorectal adenocarcinoma; Combined treatment; Long term outcome.; Neoadjuvant therapy

Indexed keywords

FLUOROURACIL; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM CANCER; RECTUM CARCINOMA; RECURRENCE FREE SURVIVAL; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84875900868     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. American Cancer Society. Colorectal Cancer Facts & Figures 2011-2013 Available from: http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-028323.pdf Last accessed on December 22, 2012.
2. NCCN Clinical Practice Guidelines in Oncology. Rectal Cancer. Fort Washington, PA: National Comprehensive Cancer Network; Version 1, 2012.
3. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M and Bedenne L: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-T4 rectal cancers: Results of FFCD 9203. J Clin Oncol 24(28): 4620-4625, 2006.
4. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A and Ollier JC: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11): 1114-1123, 2006.
5. Hartley A, Ho KF, McConkey C and Geh JI: Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. Br J Radiol 78(934): 934-938, 2005.
6. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I and de Gramont A: Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23): 2343-2351, 2004.
7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16): 2938-2947, 2000.
8. Blackstock AW, Hess S and Chaney S: Oxaliplatin: In vitro evidence of its radiation sensitizing activity: preclinical observations relevant to clinical trials. Int J Radiant Oncol Biol Phys 45: 3s, (suppl; abstr 202), 1999.
9. Arbuck SG, Ivy SP and Setser A: The revised Common Toxicity Criteria: version 2.0. Cancer Therapy Evaluation Program (CTEP website), 1999.
10. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47(1): 207-214, 1981.
11. Quirke P, Williams GT. Minimum Dataset for Colorectal Cancer Histopathology Reports. London, United Kingdom, Royal College of Pathology, 1998.
12. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
13. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
14. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
15. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H and Raab R: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17): 1731-1740, 2004.
16. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ and Wolmark N: Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP-R03. J Clin Oncol 27(31): 5124-5130, 2009.
17. Roedel C, Hofheinz R and Liersch T: Rectal cancer: State of the art in 2012. Curr Opin Oncol 24(4): 441-447, 2012.
18. Siegel R, Burock S, Wernecke KD, Kretzschmar A, Dietel M, Loy V, Koswig S, Budach V and Schlag PM: Preoperative short course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. BMC Cancer 9: 50, 2009.
19. Roedel C and Sauer R: Integration of novel agents into combined-modality treatment for rectal cancer patients. Strahlenther Onkol 183: 227-235, 2007.
20. Glynne-Jones R, Mawdsley S and Harrison M: Antiepidermal growth factor receptor radiosensitizers in rectal cancer. Anticancer Drugs 22(4): 330-340, 2011.
21. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY and Jain RK: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2): 145-147, 2004.
22. Hofheinz RD, von Gerstenberg-Helldorf B, Wenz F, Gnad U, Kraus-Tiefenbacher U, Müldner A, Hehlmann R, Post S, Hochhaus A and Willeke F: Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 23(7): 1350-1357, 2005.
23. Klautke G, Küchenmeister U, Foitzik T, Ludwig K, Prall F, Klar E and Fietkau R: Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer 94(7): 976-981, 2006.
24. Roh MS, Yothers GA, O'Connell MJ, Beart RW, Pitot HC, Shields AF, Parda DS, Sharif S, Allegra CJ, Petrelli NJ, Landry CJ, Ryan DP, Arora A, Evans TL, Soori GS, Chu L, Landes RV, Mohiuddin M, Lopa S and Wolmark N: The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 29: 2011 (suppl;abstr 3503).
25. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M and Boni L: Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29(20): 2773-2780, 2011.
26. Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Montoto-Grillot C and Conroy T: Comparison of two neoadjuvant chemotherapy regimes for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28(10): 1638-1644, 2011.
27. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G and Sauer R: Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the Germal CAO/ARO/AIO-04 randomized phase 3 trial. Lancet Oncol 13(7): 679-687, 2012.
28. Bonnetain F, Bosset J, Gerard J, Calais G, Conroy T, Mineur L, Bouche O, Maingon P, Chalet O, Radosevic-Jelic L, Methy N and Collette L: An analysis of preoperative chemoradiotherapy with 5-FU/leucovorin for T3-T4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question? J Clin Oncol 29(suppl;abstr 3506): 2011.
29. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I and Hochhaus A: Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13(6): 579-588, 2012.